Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility
Published on March 02, 2016
New York, N.Y. – March 1st, 2016 – Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), announced today that its wholly owned subsidiary, Calyxt, Inc., has closed on the purchase of a 10-acre parcel in the St. Paul suburb of Roseville to build its new headquarters facility.
The new facility, which should be operational around mid-2017, will be comprised of a 35,000 square-foot office and lab building, with greenhouses and outdoor research plots.
Calyxt, Inc., is a Minnesota-based company focused on developing healthier food products to benefit both consumers and growers.
To find out more about Calyxt, please visit their website: www.calyxt.com